ArticleNMR in biomedicine2023
Radiomics analysis of amide proton transfer-weighted and structural MR images for treatment response assessment in malignant gliomas.
Article in NMR in biomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Performance of amide proton transfer imaging to differentiate true progression from therapy-related changes in gliomas and metastases.European radiology · 2025Pooled it
- Multi-molecular saturation-transfer MR fingerprinting for differentiating tumor progression from treatment-related change in post-treatment IDH-wildtype glioblastoma: a feasibility study.Journal of neuro-oncology · 2026Article
- Robust Extrapolated Semi-Solid Magnetization Transfer Reference Fitting for Quantitative Amide Proton Transfer Imaging at 3 T: Application to Patients With Mild Cognitive Impairment and Mild Dementia.Magnetic resonance in medicine · 2026Article
- Multiparametric MRI radiomics integrating Arterial Spin Labeling, Quantitative Susceptibility Mapping, and Amide Proton Transfer imaging for differentiating glioma recurrence from post-treatment response.Frontiers in oncology · 2026Article
- Amide proton transfer weighted and diffusion weighted imaging based radiomics classification algorithm for predicting 1p/19q co-deletion status in low grade gliomas.BMC medical imaging · 2024Article
- Radiomic feature reliability of amide proton transfer-weighted MR images acquired with compressed sensing at 3T.International journal of imaging systems and technology · 2024Article
- Advances in diffuse glioma assessment: preoperative and postoperative applications of chemical exchange saturation transfer.Frontiers in neuroscience · 2024Review
- CEST2022: Amide proton transfer-weighted MRI improves the diagnostic performance of multiparametric non-contrast-enhanced MRI techniques in patients with post-treatment high-grade gliomas.Magnetic resonance imaging · 2023Article
- Review
- Innovative Value of Amide Proton Transfer Imaging in the Diagnosis and Treatment of Brain Gliomas: From Basic Principles to Clinical Applications.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
The purpose of this study was to evaluate the value of amide proton transfer-weighted (APTw) MRI radiomic features for the differentiation of tumor recurrence from treatment effect in malignant gliomas. Eighty-six patients who had suspected tumor recurrence after completion of chemoradiation or radiotherapy, and who had APTw-MRI data acquired at 3 T, were retrospectively analyzed. Using a fluid-attenuated inversion recovery (FLAIR) image-based mask, radiomics analysis was applied to the processed APTw and structural MR images. A chi-square automatic interaction detector decision tree was used for classification analysis. Models with and without APTw features were built using the same strategy. Tenfold cross-validation was applied to obtain the overall classification performance of each model. Sixty patients were confirmed as having tumor recurrence, and the remainder were confirmed as having treatment effect, at median time points of 190 and 171 days after therapy, respectively. There were 525 radiomic features extracted from each of the processed APTw and structural MR images. Based on these, the APTw-based model yielded the highest accuracy (86.0%) for the differentiation of tumor recurrence from treatment effect, compared with 74.4%, 76.7%, 83.7%, and 76.7% for T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.